Replenishment of GDF11 Reverses Cardiac Hypertrophy in Aging Animals
|
By LabMedica International staff writers Posted on 22 May 2013 |

Image: Senior author Dr. Richard Lee (left) with contributing author Dr. Amy J. Wagers (right) (Photo courtesy of Harvard University).
Experimental data collected by a team of cardiovascular disease researchers identified the decline in levels of the blood-borne protein growth differentiation factor 11 (GDF11) as contributing to deterioration of the heart muscle (cardiac hypertrophy) that occurs with advanced age and showed that restoration of GDF11 could reverse this process.
Investigators at Harvard University (Boston, MA, USA) searched for factors leading to the development of cardiac hypertrophy by using heterochronic parabiosis, a surgical technique in which joining of animals of different ages leads to a shared circulation.
The circulatory systems of old and young mice were surgically joined. After four weeks of exposure to the circulation of young mice, indicators of cardiac hypertrophy in old mice dramatically regressed. Changes included reduced cardiomyocyte size and molecular remodeling. This reversal of age-related hypertrophy was not attributable to hemodynamic or behavioral effects of the parabiosis procedure, implicating a blood-borne factor.
The investigators used modified aptamer-based proteomics to identify the TGF-beta superfamily member GDF11 as a circulating factor in young mice that declined with age. Aptamers are nucleic acid species that have been engineered through repeated rounds of in vitro selection to bind to various molecular targets such as small molecules, proteins, and nucleic acids. Aptamers are useful in biotechnological and therapeutic applications as they offer molecular recognition properties that rival that of antibodies. In addition to their discriminate recognition, aptamers offer advantages over antibodies as they can be engineered completely in a test tube, are readily produced by chemical synthesis, possess desirable storage properties, and elicit little or no immunogenicity in therapeutic applications.
GDF11 is a member of the bone morphogenetic protein (BMP) family and the TGF-beta (transforming growth factor beta) superfamily. This group of proteins is characterized by a polybasic proteolytic processing site, which is cleaved to produce a mature protein containing seven conserved cysteine residues. The members of this family are regulators of cell growth and differentiation in both embryonic and adult tissues. Studies in animals suggest that this protein is involved in mesodermal formation and neurogenesis during embryonic development.
Results published in the May 9, 2013, online edition of the journal Cell revealed that treatment of old mice that restored GDF11 to youthful levels replicated the effects of parabiosis by reversing age-related hypertrophy, a finding that implies a possible therapeutic use for this protein in geriatric medicine.
"There has been evidence that circulating bloodstream factors exist in mammals that can rejuvenate tissues, but they have not been identified. This study found the first factor like this," said senior study author Dr. Richard Lee, professor of medicine at Harvard University.
Related Links:
Harvard University
Investigators at Harvard University (Boston, MA, USA) searched for factors leading to the development of cardiac hypertrophy by using heterochronic parabiosis, a surgical technique in which joining of animals of different ages leads to a shared circulation.
The circulatory systems of old and young mice were surgically joined. After four weeks of exposure to the circulation of young mice, indicators of cardiac hypertrophy in old mice dramatically regressed. Changes included reduced cardiomyocyte size and molecular remodeling. This reversal of age-related hypertrophy was not attributable to hemodynamic or behavioral effects of the parabiosis procedure, implicating a blood-borne factor.
The investigators used modified aptamer-based proteomics to identify the TGF-beta superfamily member GDF11 as a circulating factor in young mice that declined with age. Aptamers are nucleic acid species that have been engineered through repeated rounds of in vitro selection to bind to various molecular targets such as small molecules, proteins, and nucleic acids. Aptamers are useful in biotechnological and therapeutic applications as they offer molecular recognition properties that rival that of antibodies. In addition to their discriminate recognition, aptamers offer advantages over antibodies as they can be engineered completely in a test tube, are readily produced by chemical synthesis, possess desirable storage properties, and elicit little or no immunogenicity in therapeutic applications.
GDF11 is a member of the bone morphogenetic protein (BMP) family and the TGF-beta (transforming growth factor beta) superfamily. This group of proteins is characterized by a polybasic proteolytic processing site, which is cleaved to produce a mature protein containing seven conserved cysteine residues. The members of this family are regulators of cell growth and differentiation in both embryonic and adult tissues. Studies in animals suggest that this protein is involved in mesodermal formation and neurogenesis during embryonic development.
Results published in the May 9, 2013, online edition of the journal Cell revealed that treatment of old mice that restored GDF11 to youthful levels replicated the effects of parabiosis by reversing age-related hypertrophy, a finding that implies a possible therapeutic use for this protein in geriatric medicine.
"There has been evidence that circulating bloodstream factors exist in mammals that can rejuvenate tissues, but they have not been identified. This study found the first factor like this," said senior study author Dr. Richard Lee, professor of medicine at Harvard University.
Related Links:
Harvard University
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
VOCs Show Promise for Early Multi-Cancer Detection
Early cancer detection is critical to improving survival rates, but most current screening methods focus on individual cancer types and often involve invasive procedures. This makes it difficult to identify... Read more
Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
Kidney disease is typically diagnosed through blood or urine tests, often when patients present with symptoms such as blood in urine, shortness of breath, or weight loss. While these tests are common,... Read moreMolecular Diagnostics
view channel
Simultaneous Analysis of Three Biomarker Tests Detects Elevated Heart Disease Risk Earlier
Accurately identifying individuals at high risk of heart attack remains a major challenge, especially when traditional indicators like cholesterol and blood pressure appear normal. Elevated levels of three... Read more
New Biomarker Panel to Improve Heart Failure Diagnosis in Women
Heart failure affects millions worldwide, yet many women are still misdiagnosed or diagnosed too late. Although heart failure broadly means the heart cannot pump enough blood to the body’s cells, its two... Read moreHematology
view channel
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more
Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read moreImmunology
view channel
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read more
Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
Immunotherapy has revolutionized cancer care by harnessing the immune system to fight tumors, yet predicting who will benefit remains a major challenge. Many patients undergo costly and taxing treatment... Read moreMicrobiology
view channel
15-Minute Blood Test Diagnoses Life-Threatening Infections in Children
Distinguishing minor childhood illnesses from potentially life-threatening infections such as sepsis or meningitis remains a major challenge in emergency care. Traditional tests can take hours, leaving... Read more
High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample
Gastrointestinal (GI) infections are among the most common causes of illness worldwide, leading to over 1.7 million deaths annually and placing a heavy burden on healthcare systems. Conventional diagnostic... Read morePathology
view channel
Hydrogel-Based Technology Isolates Extracellular Vesicles for Early Disease Diagnosis
Isolating extracellular vesicles (EVs) from biological fluids is essential for early diagnosis, therapeutic development, and precision medicine. However, traditional EV-isolation methods rely on ultra... Read more
AI Tool Improves Accuracy of Skin Cancer Detection
Diagnosing melanoma accurately in people with darker skin remains a longstanding challenge. Many existing artificial intelligence (AI) tools detect skin cancer more reliably in lighter skin tones, often... Read moreTechnology
view channel
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read more
AI-Powered Biosensor Technology to Enable Breath Test for Lung Cancer Detection
Detecting lung cancer early remains one of the biggest challenges in oncology, largely because current tools are invasive, expensive, or unable to identify the disease in its earliest phases.... Read moreIndustry
view channel
Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics
Co-Diagnostics, Inc. (Salt Lake City, UT, USA) has formed a new artificial intelligence (AI) business unit to integrate the company's existing and planned AI applications into its Co-Dx Primer Ai platform.... Read more








